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Objectives: Type 2 diabetes (T2D) is associated with chronic, low grade inﬂammation. Activation of the NLRP3 inﬂammasome and secretion of
its target interleukin-1b (IL-1b) have been implicated in pancreatic b cell failure in T2D. Speciﬁc targeting of the NLRP3 inﬂammasome to prevent
pancreatic b cell death could allow for selective T2D treatment without compromising all IL-1b-associated immune responses. We hypothesized
that treating a mouse model of T2D with MCC950, a compound that speciﬁcally inhibits NLRP3, would prevent pancreatic b cell death, thereby
preventing the onset of T2D.
Methods: Diabetic db/db mice were treated with MCC950 via drinking water for 8 weeks from 6 to 14 weeks of age, a period over which they
developed pancreatic b cell failure. We assessed metabolic parameters such as body composition, glucose tolerance, or insulin secretion over the
course of the intervention.
Results: MCC950 was a potent inhibitor of NLRP3-induced IL-1b in vitro and was detected at high levels in the plasma of treated db/db mice.
Treatment of pre-diabetic db/db mice with MCC950, however, did not prevent pancreatic dysfunction and full onset of the T2D pathology. When
examining the NLRP3 pathway in the pancreas of db/db mice, we could not detect an activation of this pathway nor increased levels of its target
IL-1b.
Conclusions: NLRP3 driven-pancreatic IL-1b inﬂammation does not play a key role in the pathogenesis of the db/db murine model of T2D.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes mellitus is growing world-wide and is expected to affect
almost 600 million people by 2035 [1]. Type 2 Diabetes (T2D) is
recognized as a chronic inﬂammatory disease, and it is now estab-
lished that inﬂammation and immune cell dysfunction are strongly
associated with both insulin resistance and insulin secretion
dysfunction [2]. The ability of immune cells to affect pancreatic
function and, more speciﬁcally, b cell insulin-secretory activity in is-
lets, is well established in the context of type 1 diabetes [3,4]. In
contrast, the role of inﬂammation and immune cells in the pathology of
T2D is a relatively recent phenomenon (for review see [5]). Speciﬁcally,
macrophages have been shown to inﬁltrate pancreatic islets both in
T2D patients as well as in rodent models of insulin resistance and
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In particular, the pro-inﬂammatory cytokine interleukin-1b (IL-1b) has
been highlighted as a potent driver of beta cell dysfunction [9,10]. IL-
1b secretion is triggered in the islet in response to high level of
glucose, initiating a pro-inﬂammatory milieu that contributes to the
recruitment and activation of macrophages, which, in turn, sustain islet
inﬂammation [9]. Indeed, suppressing macrophage recruitment in db/
db mice (that harbor a mutation of the leptin receptor leading to hy-
perphagia, obesity and eventually b cell failure) using clodronate li-
posomes improved insulin secretion [11]. Mature IL-1b is mainly
produced through the multi-protein inﬂammasome complexes such as
NOD-like receptor pyrin domain containing protein 3 (NLRP3) inﬂam-
masome. Pro-inﬂammatory danger-associated molecular patterns
(DAMPs), endogenous molecules such as extracellular ATP, or uric acid
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recruitment of the adaptor protein apoptosis-associated speck-like
protein containing a CARD (ASC) and pro-caspase-1. The assembly of
the NLRP3 inﬂammasome results in the cleavage and activation of
caspase-1 which in turn activates the precursor form of IL-1b through
proteolytic cleavage [9]. In the context of T2D, several different stimuli
have been proposed to trigger pancreatic NLRP3 activation and
increased IL-1b. We have shown that accumulation of islet amyloid
polypeptide (IAPP), a protein known to accumulate into amyloid de-
posits in the pancreas of T2D patients, could activate the NLRP3
inﬂammasome and promote IL-1b production [12]. In addition to IAPP,
saturated fatty acids, ATP from apoptotic cells, endocannabinoids, ER
stress, and oxidative stress have also been reported to potentiate
NLRP3-induced IL-1b production and contribute to islet inﬂammation
[9]. Targeting IL-1b signaling using Anakinra (IL-1 receptor antagonist)
and Canakinumab (anti-IL-1b antibody) to treat T2D patients yielded
modest but promising results [13e15]. Speciﬁc targeting of the NLRP3
inﬂammasome to prevent pancreatic cell death, however, could be a
viable treatment strategy for T2D, because it would not compromise IL-
1b-associated immune function, initiated by pathways other than
NLRP3. We have shown that the orally available small molecule
MCC950 potently and speciﬁcally inhibits NLRP3 activation and that it
is efﬁcacious in several pre-clinical models of inﬂammatory diseases
including NLRP3-driven auto-inﬂammatory conditions [16e21]. We
hypothesized that treating a diabetic mouse with MCC950 would
prevent the pancreatic islets death and delay, if not completely block,
the onset of T2D.
2. MATERIAL AND METHODS
2.1. Mouse models and drug treatment
db/db and db/þ littermate control mice (BKS.Cg-Dock7<m> þ/þ
Lepr<db>/J) were purchased from Jackson laboratories (USA) at 4
weeks of age and left to acclimatize for 2 weeks. All mice were housed
at the Alfred Medical Research and Education Precinct Animal Centre in
a pathogen free facility under controlled environmental conditions and
exposed to a 12:12 h light:dark cycle. Mice were fed a normal chow
diet (Specialty Feeds, Australia) and provided with food and water ad
libitum. From 6 weeks of age, mice received MCC950 (40 mg/kg) via
drinking water for a period of 8 weeks. Water intake was recorded
daily for each cage. The dose of MCC950 was adjusted every 3 days
according to mice weight gain/loss and averaged water intake per
cage. Animal experiments were approved by the Alfred Medical
Research and Education Precinct Animal Ethics Committee and con-
ducted in accordance with the National Health and Medical Research
Council of Australia Guidelines for Animal Experimentation.
2.2. Metabolic measurements
2.2.1. Plasma insulin measurements
Insulin concentrations were measured using a Mouse Ultrasensitive
Insulin ELISA kit (ALPCO, Salem, NH, USA) according to manufacturer’s
instructions.
2.2.2. Body composition
Mouse body composition (fat mass (FM) and lean body mass (LBM))
were measured weekly with a 4-in-1 EchoMRI body composition
analyzer (Columbus Instruments, USA) and standard laboratory scales.
2.2.3. oral Glucose Tolerance Test (oGTT)
OGTT (2 g/kg LBM) were performed in 5 h (for week 2 oGTT) or 12 h
(for week 7 oGTT) fasted mice as previously described [22].MOLECULAR METABOLISM 10 (2018) 66e73  2018 The Authors. Published by Elsevier GmbH. This is an ope
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Pancreatic islets from 16 weeks old db/þ and db/db mice were iso-
lated as previously described [23]. Total RNA was isolated from tissues
with Tri Reagent (Sigma Aldrich) and reverse transcribed to cDNA
with the use of random hexamers. Gene expression analysis was
performed by Real-time PCR on a 7500 fast sequence detector
(Applied Biosystems) using TaqMan gene expression assays (Applied
Biosystems), including an 18S probe and primers for housekeeping
measurements (Taqman references are included in Supplementary
Fig. 3).
2.4. Blood parameters
For hematological assessment, a small volume (20 mL) of whole blood
was diluted 1:7 in Sysmex CELLPACK (Sysmex, Japan) diluent and
assessed using an automated hematology analyzer (Sysmex XS-1000i,
Japan).
2.5. MCC950 quantiﬁcation
MCC950 was measured in the plasma by Liquid chromatography-
tandem mass spectrometry as previously described [16] for plasma.
For tissue analysis, fat, liver and kidney were weighed and homoge-
nised in saline using a Qiagen tissuelyser. The quantiﬁcation was
performed as described in the Supplementary Material.
2.6. Western blotting
Renal cortex was isolated from frozen kidney samples and western
blotting was performed on tissue homogenates as previously
described [24] and quantiﬁed relative to relevant loading controls.
2.7. In vitro experiment
Bone marrow derived macrophages were obtained and cultured as
previously described [25]. Cells were treated with LPS, ATP andMCC950
as described in the ﬁgure legend before the supernatant was harvested
and used to measure IL-1b using the R&D Duoset Mouse ELISA.
2.8. Statistical analysis
Data are presented as mean standard error of the mean (SEM). Two-
way analysis of variance (ANOVA) was used to detect main effects for
genotype (db/þ vs. db/db) and treatment (vehicle vs. MCC950), Post-
hoc analyses (Holm-Sidak) were performed when a signiﬁcant inter-
action was detected. Analyses were performed using a statistical
computer program (Sigma Stat Version 3.5). p< 0.05 was considered
statistically signiﬁcant.
3. RESULTS
3.1. MCC950 inhibits IL-1b secretion in BMDM stimulated with
NLRP3 inﬂammasome activators
We ﬁrst aimed to verify the potency of MCC950 to inhibit the NLRP3
inﬂammasome in our experimental conditions. We pre-treated bone
marrow derived macrophages with LPS in order to induce Il1b gene
expression and pro-IL-1b production. We next treated these cells with
MCC950 before inducing the NLRP3 inﬂammasome activation with ATP.
We observed a near complete prevention of ATP-induced NLRP3-
mediated IL-1b release in the cells treated with the two doses of
MCC950 conﬁrming its strong inhibitory potency (Supplementary Fig. 1)
3.2. MCC950 does not impact body weight or fat and lean mass in
db/db mice
We next proceeded to test the in vivo effect of MCC950 in a mouse
model of T2D. db/db and db/þ (lean littermate) mice were fed a chown access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 67
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Figure 1: MCC950 does not impact body weight or fat and lean mass in db/db mice. 6 weeks old db/db mice were given 40 mg/kg MCC950 through their drinking water for
an 8 weeks period. (A) Body weight (B) fat mass and (C) lean mass were assessed by EchoMRI a week before and weekly throughout the treatment period. Data presented as
Mean  SEM, n ¼ 10.
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Figure 2: MCC950 is bioavailable in plasma but does not affect immune cell proﬁle in db/db mice. 6 weeks old db/db mice were given 40 mg/kg MCC950 through their
drinking water for an 8 weeks period. (A) Red blood cell parameters (B) White blood cell, platelets, lymphocyte counts, and (C) leukocyte counts were measured in the blood at the 8
weeks endpoint. Data presented as Mean  SEM, n ¼ 10. Statistical analysis by 2 way ANOVA, *p < 0.05; ***p < 0.001 Main effect for db/db vs db/þ.
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through their drinking water. As expected, the db/db mice became
severely obese with a markedly increased fat mass, and decreased
lean mass, compared with db/þ mice (Figure 1). Treatment of both
groups of mice with MCC950 did not, however, affect these param-
eters (Figure 1).
3.3. MCC950 is bioavailable in plasma and tissues but does not
affect immune cell proﬁle in db/db mice
After observing no impact on the animals’ body composition in
response to MCC950 treatment, we aimed to verify the bioavailability
of MCC950. We analyzed plasma from all mice at termination of the
intervention and assessed circulating levels of MCC950 using liquid
chromatography-tandem mass spectrometry. As expected, we
detected high circulating levels of our compound in both db/þ and db/
db treated groups as expected (Supplementary Fig. 2) consistent with
previous pharmacokinetic studies that have shown efﬁcacy of the
compound at this dose [16]. Interestingly, we observed a w5 fold
higher (P < 0.05) plasma MCC950 concentration in db/þ compared
with db/db mice (Supplementary Fig. 2), suggesting that some of the
compound might get trapped in the large fat stores in the obese db/db
mice. Hence, we set to investigate the amount of compound in several
tissues as well as in urine (Supplementary Fig. 2). Surprisingly, the
compound was found in negligible quantities in the visceral fat depot of
both db/þ and db/db and the liver and kidney presented with the same
pattern as the plasma with up to 10 times more compound being
located in the liver of the db/þ compared to the db/db mice. However,
a major result arise from the urine analysis. db/db mice excreted
MCC950 metabolite at a higher rate (1.5 fold versus db/þ) and given
that their urine output was almost 10 times higher (data not shown), it
reveals that the discrepancy between the groups in relation toFigure 3: MCC950 does not improve glucose metabolism nor prevent pancreatic islet
their drinking water for an 8 week period. Glycemia (A) and circulating insulin levels (B) w
period. (C) Water consumption per mouse per day was measured in the 3 different cages
following a 5 h fast at 2 weeks of treatment (D) and a 12 h fast at 7 weeks of treatment (E
n ¼ 10. Statistical analysis by 2 way ANOVA, ***p < 0.001 Main effect for db/db vs db/
70 MOLECULAR METABOLISM 10 (2018) 66e73  2018 The Authors. Published by Elsevier GmbH. Thicirculating levels was due to the compound being excreted in db/db
mice at a higher rate. Importantly, the circulating concentration in the
db/db mice was nonetheless >1000 ng/mL, which was proven suf-
ﬁcient to inhibit NLRP3 in vivo [16]. We next determined whether
MCC950 administration could result in any side effects by measuring
several blood markers. MCC950 did not affect either hemoglobin, or
hematocrit concentrations, nor did it affect red blood cells number
(Figure 2A). White blood cells, including platelets and lymphocytes
(Figure 2B) or circulating monocytes, neutrophils, eosinophils, and
basophils (Figure 2C) were also unaffected by the treatment. Of note,
the db/db mice displayed lymphocytopenia (Figure 2B) and mild
neutrophilia, consistent with previous reports [26,27].
3.4. MCC950 does not improve glucose metabolism nor prevent
pancreatic islet failure in db/db mice
We next determined whether MCC950 could better maintain glucose
homeostasis in db/db mice. Six week old db/db mice, displayed both
frank hyperglycemia (Figure 3A) and markedly increased water con-
sumption (Figure 3C) throughout the intervention period compared with
db/þ mice. Importantly, MCC950 treatment did not affect these pa-
rameters (Figure 3A,C). The failure of MCC950 to affect hyperglycemia
was associated with a lack of effect on insulin secretion (Figure 3B).
Indeed, we measured fasting insulin levels along the course of the
intervention and MCC950 treatment was unable to prevent the pro-
gressive decrease of insulin secretion observed in the db/db mice, an
indication of the transition from b cell compensation to b cell failure
(Figure 3B).
We next measured glucose tolerance by performing oral glucose
tolerance test (OGTT; 2 g/kg LBM) at both week 2 and week 7 of the
treatment period. Consistent with the failing pancreatic function of
both db/db groups and the fasting glycemia observations, MCC950failure in db/db mice. 6 weeks old db/db mice were given 40 mg/kg MCC950 through
ere measured after a 5 h (time points marked )^ or 12 h (all other time points) fasting
of each experimental group. (DeF) Glucose tolerance was assessed through an oGTT
) and was used to generate area under the curve (F). Data presented as Mean  SEM,
þ.
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had no effect on the severe glucose intolerance displayed by db/db
relative to db/þ mice during the OGTT at both intervention periods
(Figure 3DeF).
3.5. db/db mice do not display inﬂammasome activation in
pancreatic islets
Since MCC950 inhibited NLRP3 activation in vitro (Supplementary
Fig. 1) and was clearly bioavailable (Supplementary Fig. 2), our data
raised the possibility that, in this particular model, NLRP3 was not
activated in the pancreas of db/db mice. Indeed, previous data from
our laboratory found no difference in IL-1b expression in pancreatic
islets of 6 weeks old db/db compared to db/þ islets [28]. In addition,
we isolated pancreatic islets isolated from db/þ and db/db mice at
both 6 and 16 weeks and analyzed the mRNA expression of NLRP3 as
well as IL-1b in the islets of the 16 weeks old animals (Figure 4A,B).
Given the current literature and work from our own group [12], we
were surprised to observe no increase in the mRNA expression of
either IL-1b or NLRP3 in the cDNA extracted from db/db islets
compared with that obtained the db/þ islets (Figure 4A,B). Of note, IL-
1b expression at 16 weeks was quite heterogeneous in the db/db
group, probably reﬂecting different stages of the diabetes progression
in these mice. Interestingly, and in line with previously published data
[29], we were able to detect increased inﬂammasome components in
the renal cortex of db/db mice compared with db/þ mice (Figure 4C).
We could not detect a signiﬁcant effect of MCC950 administration onFigure 4: MCC950 treatment in db/db mice does not impact pancreatic inﬂammaso
pancreatic islet of 16 weeks old db/þ and db/db mice. (B) Gene expression for NLRP3 w
weeks old db/db mice were given 40 mg/kg MCC950 through their drinking water for an 8 w
end of the treatment period. Data presented as Mean  SEM, AeB; n ¼ 11e12; C; n ¼
MOLECULAR METABOLISM 10 (2018) 66e73  2018 The Authors. Published by Elsevier GmbH. This is an ope
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the drug in the kidney (Figure 4C and Supplementary Fig. 2).
4. DISCUSSION
Activation of the NLRP3 inﬂammasome has been implicated in the
pathology of obesity and insulin resistance [30e32]. These previous
studies demonstrated a role for the NLRP3 inﬂammasome in the ad-
ipose tissue and liver and mostly attributed its activation and the
associated secretion of IL-1b to inﬁltrating macrophages in these
tissues.
In addition, the NLRP3 inﬂammasome has been increasingly studied
for its role in pancreatic dysfunction in the context of T2D [5]. The
activation of this inﬂammasome complex leading to the production of
the pro-inﬂammatory cytokine IL-1b has been described in the
pancreas in response to several different stimuli. In the pancreatic
islet, it appears that both glucose stressed-b cells as well as resident
pro-inﬂammatory macrophages contribute to increased levels of IL-
1b and the subsequent insulin secretion impairment [9]. Reports are
still unclear whether the myeloid-derived or b cell-produced IL-1b, if
not both, is the culprit in b-cell dysfunction. Interestingly, a recent
report studying diabetic nephropathy in db/db mice also suggested a
strong role for the NLRP3 inﬂammasome and the subsequent IL-1b
secretion in non-myeloid cells. Indeed, mice lacking NLRP3 are
protected from diabetic nephropathy, even when transplanted withme components. (A) Gene expression for IL-1b and NLRP3 was measured in isolated
as measured in isolated pancreatic islet of 6 weeks old db/þ and db/db mice. (C) 16
eeks period. IkBa and NLRP3 were measured on renal cortex by western blotting at the
5e8.
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bone marrow into wild-type animals fails to prevent diabetic ne-
phropathy [29]. This report emphasized a role for IL-1b in the diabetic
pathology of db/db mice as they presented a six-fold increase in the
cytokine circulating concentration between 4 and 12 weeks of age in
these animals [29]. These previous publications prompted us to
examine the efﬁcacy of our speciﬁc NLRP3 inhibitor in the db/db mice
in order to arrest the transition from b-cell compensation to failure.
We were, therefore surprised that, in our hands neither NLRP3 nor IL-
1b mRNA expression were elevated in the islets from db/db mice. In
retrospect, it was not surprising that MCC950 had no effect in this
experimental model of T2D.
Our data contrast a number of reports indicative of an NLRP3-
dependent mechanism to explain IL-1b activation and its role in
pancreatic dysfunction. Youm et al. demonstrated that aged mice fed
a high fat diet until reaching one year of age displayed ASC depen-
dent glucose intolerance, but, more importantly, they observed a
conserved insulin secretory function in aged mice on a high fat diet
lacking the adaptor ASC or NLRP3 itself [33]. It is critically important,
however, to note that in this previous study the authors did not use
littermate controls for the ASC/ and NLRP3/ mice. This could
represent an artifact, as it was shown that basal and challenged
insulin levels and glucose metabolism are strongly inﬂuenced by the
strains but also more importantly by the sub-strain of C57Bl/6 mouse
used [34,35]. Indeed, data from our laboratory have shown that
metabolic phenotype differences when comparing genetic mouse
models are abolished when appropriate littermate control studies are
performed [25]. Moreover, the work of others [21] has demonstrated
that glucose tolerance and insulin secretion capacity could be
signiﬁcantly different in two sub-strains studied side by side on a
high fat diet [35].
Interestingly, Kim et al. also proposed a role for the NLRP3 inﬂam-
masome in the same model used herein as they treated db/db mice
with the modiﬁed form of Vitamin E g-tocotrienol (gT3) [36]. They
report an improved glucose tolerance accompanied by an enhanced
glucose stimulated insulin secretion in vivo. Importantly, however, they
did not demonstrate the activation of NLRP3 in the db/db pancreatic
islet and their gT3 compound appears to have several targets in
addition to NLRP3, making it difﬁcult to ascertain the role of this
inﬂammasome in the observed metabolic effects. Indeed, they also
report a signiﬁcantly decreased food intake that could likely mediate
the decreased fasting glycemia, given the fasting insulin levels were
not different between treated and control db/db animals. In addition,
they also observed increased AMPK activation in the gT3-treated mice,
a known metabolic activator associated with improved glucose
metabolism [37,38].
Of note, MCC950 targets the NLRP3 inﬂammasome activation meaning
that not only the IL-1b inﬂammatory pathway but also IL-18 driven
inﬂammation or pyroptosis would be inhibited, ruling out a role for
these pathways as well in the db/db model [39].
Finally, recent reports by Donath and colleagues indicate that the role
of IL-1b might not be just detrimental in the pancreas as they report
that IL-1b is secreted physiologically after a meal. Indeed, mice
deﬁcient for IL-1b exhibited decreased insulin levels in response to
refeeding or to a high fat diet [40]. This might add some complexity to
the pharmaceutical ﬁeld considering IL-1b as a therapeutic target for
diabetes.
In conclusion, it appears that the NLRP3 inﬂammasome is not
responsible for the b-cell insulin secretory failure observed in the
db/db mouse model of T2D. The use of a genetic model lacking the
leptin receptor such as the db/db mouse might explain part of the72 MOLECULAR METABOLISM 10 (2018) 66e73  2018 The Authors. Published by Elsevier GmbH. Thidiscrepancy as leptin signaling and the downstream STAT3
pathway have been implicated in inﬂammation modulation [41,42].
However, given the increasing number of human studies targeting
IL-1b and other inﬂammation components for the treatment of T2D
[13,43e46], our data caution the use of db/db mice as an
appropriate pre-clinical model of T2D, particularly when testing the
efﬁcacy of drugs that target insulin secretory pathways and islet
inﬂammation.
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